Company / Cash & Equivalents
PANACEA LIFE SCIENCES HOLDINGS, INC. Cash & Equivalents History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$100.9K
FY2023
5-year range
$7.0K / $100.9K
FY2019-FY2023
Trend
+1351.9%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +1352% YoY in FY2023, a notable deviation from the 7-year average annual change of +318%.
Based on SEC 10-K filings.
$100,922 in FY2023 with a 5-year CAGR of +120.0%.
Improved from $19,774 to $100,922 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +6.1%
- 5-Year CAGR
- +120.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +120.0%, indicating consistent growth.
- In FY2023, cash & equivalents increased 1351.9% year-over-year.
- Peak cash & equivalents was recorded in FY2016.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | $100.9K | +1351.9% |
| FY2022 | $7.0K | -64.8% |
| FY2021 | $19.8K | -76.6% |
| FY2020 | $84.4K | +358.5% |
| FY2019 | $18.4K | +839.0% |
| FY2018 | $2.0K | -98.8% |
| FY2017 | $161.2K | -84.7% |
| FY2016 | $1.1M | - |
| FY2015 | $0 | - |
As of FY2023 · SEC Form 10-K · Last checked Jun 29, 2026